NDA 211215 · Maia Pharms INC
Angiomax Rtu
Bivalirudin · Intravenous · Anti-coagulant; Direct Thrombin Inhibitor
Last checked: Nov 20, 2026Latest source record: May 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jul 25, 2019
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
74
21 Phase 3, 6 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Bivalirudin" as an intervention, any sponsor and status, largest first.
- Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093158 · 13,800 participants · Start Aug 2003
Drug: Angiomax (bivalirudin) anticoagulant · For: Unstable Angina; Myocardial Infarction; Acute Disease
Sites: New York, New York
- Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCIPivotal-lookingCompleted
Shenyang Northern HospitalAcademic, hospital or other
NCT03822975 · 6,016 participants · Start Feb 14, 2019 · Primary completion May 7, 2022
Drug: Bivalirudin; unfractionated Heparin · For: ST Elevation Myocardial Infarction
Sites: Bengbu, China; Fuyang, China; Haozhou, China · 85 sites in all
- Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEARTPivotal-lookingCompleted
Uppsala UniversityAcademic, hospital or other
NCT02311231 · 6,012 participants · Start Jun 2014 · Primary completion Mar 2017
Drug: bivalirudin; Heparin · For: ST-segment Elevation Myocardial Infarction; Non ST-segment Elevation Myocardial Infarction
Sites: Lund, Sweden
- Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary SyndromesPivotal-lookingNot yet recruiting
Shenyang Northern HospitalAcademic, hospital or other
NCT07383155 · 5,270 participants (planned) · Start Feb 1, 2026 · Primary completion Dec 31, 2027
Drug: Anticoagulant Therapy · For: Percutaneous Coronary Intervention; High Bleeding Risk; Acute Coronary Syndromes and 1 more
- Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)Pivotal-lookingCompleted
Deutsches Herzzentrum MuenchenAcademic, hospital or other
NCT00262054 · 4,570 participants · Start Nov 2005 · Primary completion Feb 2008
Drug: Bivalirudin; Un-fractionated heparin · For: Coronary Disease; Angina Pectoris
Sites: Bad Krozingen, Germany; Bad Segeberg, Germany; Munich, Germany · 4 sites in all
- Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial InfarctionPivotal-lookingCompleted
Cardiovascular Research Foundation, New YorkAcademic, hospital or other
NCT00433966 · 3,602 participants · Start Mar 2005 · Primary completion Jun 2008
Drug: Bivalirudin; Unfractionated heparin · For: Myocardial Infarction
Sites: Greensboro, North Carolina
- A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCIPivotal-lookingTerminated
Regado Biosciences, Inc.Industry
NCT01848106 · 3,232 participants · Start Sep 2013 · Primary completion Aug 2014
Drug: pegnivacogin/anivamersen; Bivalirudin · For: Coronary Artery Disease
Sites: Rapid City, South Dakota
- Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCIPivotal-lookingCompleted
Beijing Anzhen HospitalAcademic, hospital or other
NCT03664180 · 2,989 participants · Start Jan 11, 2019 · Primary completion Nov 23, 2022
Drug: Bivalirudin; Enoxaparin and 4 more · For: STEMI - ST Elevation Myocardial Infarction
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures.
Hu Y, Liu AY, Zhang L, et al. · J Vasc Surg 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.
Stone GW, Valgimigli M, Erlinge D, et al. · J Am Coll Cardiol 2024 · Meta-Analysis, Comparative Study
- Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation.
Huang D, Guan Q, Qin J, et al. · Perfusion 2023 · Meta-Analysis
- Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.
Hasegawa D, Sato R, Prasitlumkum N, et al. · ASAIO J 2023 · Systematic Review, Meta-Analysis
- Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia.
Nilius H, Kaufmann J, Cuker A, et al. · Am J Hematol 2021 · Comparative Study, Meta-Analysis
- Meta-analysis of bivalirudin versus heparin in transradial coronary interventions.
Kheiri B, Rao SV, Osman M, et al. · Catheter Cardiovasc Interv 2020 · Meta-Analysis, Systematic Review
Sponsor: Maia Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.